Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Biomed Pharmacother. 2019 Oct 9;120:109468. doi: 10.1016/j.biopha.2019.109468

Figure 2:

Figure 2:

Cytotoxicity of JS-K in WT OVCAR-8 (■-■) and in NCI/ADR-RES (R, •-•) tumor cells (Panel A). Effects of JS-K (25 nM, •-•) and (50 nM, Δ-Δ) on ADR cytotoxicity (■-■) in NCI/ADR-RES tumor cells (Panel B), and effects of JS-K on ADR cytotoxicity in WT OVCAR-8 tumor cells (Panel C) following 72 h of drug treatment. Cells were counted as described in the methods section. Values represent three separate experiments carried out in duplicates. ***, ** and * p values ≤ 0.001, 0.005, and ≤ 0.05, respectively, compared with concentration-matched samples.